Oral delivery of therapeutic protein/peptide for diabetes-Future perspectives

International Journal of Pharmaceutics

Volumn 440, Issue 1, 2013, Pages 48-62

  Rekha, M R ^a   Sharma, Chandra P ^a  

^a SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

Author keywords

Diabetes; Exendin 4; Glucagon like peptide 1; Insulin; Nanoparticles; Oral delivery

Indexed keywords

1,2,3,4 TETRAHYDRO 1 NAPHTHOIC ACID 4 (4 ISOPROPYLPIPERAZINOCARBONYL)PHENYL ESTER; APROTININ; BACITRACIN; CALCIUM CHELATING AGENT; CAMOSTAT MESILATE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOCHOLATE SODIUM; HEMOGLOBIN A1C; INCRETIN; INSULIN; LIRAGLUTIDE; METFORMIN; NANOPARTICLE; PEPTIDE; PEPTIDE YY; POLYMER; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEINASE INHIBITOR; SOYBEAN TRYPSIN INHIBITOR; SULFONYLUREA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONULA OCCLUDENS PROTEIN;

ACIDITY; ALLERGY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG PENETRATION; DRUG TRANSPORT; EDEMA; ENDOCYTOSIS; ENZYMATIC DEGRADATION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; INTESTINE EPITHELIUM; LIPODYSTROPHY; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SMALL INTESTINE ABSORPTION; TIGHT JUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSCYTOSIS;

ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL HORMONES; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; PEPTIDES; VENOMS;

EID: 84871617217     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.03.056     Document Type: Article

References (143)

1. T.E. Adrian, G.L. Ferri, A.J. Bacarese-Hamilton, H.S. Fuessl, J.M. Polak, and S.R. Bloom Human distribution and release of a putative new gut hormone, peptide YY Gastroenterology 89 1985 1070 1077
2. V. Agarwal, S. Nazzal, I.K. Reddy, and M.A. Khan Transport studies of insulin across rat jejunum in the presence of chicken and duck ovomucoid J. Pharm. Pharmacol. 53 2001 1131 1138
3. V. Agarwal, I.K. Reddy, and M.A. Khan Oral delivery of proteins: effect of chicken and duck ovomucoid on the stability of insulin in the presence of α-chymotrypsin and trypsin Pharm. Pharmacol. Commun. 6 2000 223 227
4. B. Ahrén GLP-1 for type 2 diabetes Exp. Clin. Res. 317 2011 1239 1245
5. A.J. Almeida, and E.B. Souto Solid lipid nanoparticles as a drug delivery system for peptides and proteins Adv. Drug Deliv. Rev. 59 2007 478 490
6. J.M. Anderson, and C.M. Van Itallie Tight junctions and the molecular basis for regulation of paracellular permeability Am. J. Physiol. 269 1995 G467 G475
7. Y. Aoki, M. Morishita, K. Asai, B. Akikusa, S. Hosoda, and K. Takayama Region-dependent role of the mucous/glycocalyx layers in insulin permeation across rat small intestinal membrane Pharm. Res. 22 2005 1854 1862
8. A. Bernkop-Schnürch, C.E. Kast, and M.F. Richter Improvement in the mucoadhesive properties of alginate by the covalent attachment of cysteine J. Controlled Release 71 2001 277 285
9. A. Bernkop-Schnürch, and M.E. Krajicek Mucoadhesive polymers as platforms for peroral peptide delivery and absorption: synthesis and evaluation of different chitosan-EDTA conjugates J. Controlled Release 50 1998 215 223
10. A. Bernkop-Schnürch, A. Weithaler, K. Albrecht, and A. Greimel Thiomers: Preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system Int. J. Pharm. 317 2006 76 81
11. J. Blanchette, N. Kavimandan, and N.A. Peppas Principles of transmucosal delivery of therapeutic agents Biomed. Pharmacother. 58 2004 142 151
12. A. Bond Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus Proc. (Bayl Univ. Med. Cent.) 19 2006 281 284
13. E. Bosi, P. Lucotti, E. Setola, L. Monti, and P.M. Piatti Incretin-based therapies in type 2 diabetes: a review of clinical results Diabetes Res. Clin. Pract. 82 2008 102 107
14. P.L. Brubaker Incretin-based therapies: mimetics versus protease inhibitors Trends Endocrinol. Metab. 18 2007 240 245
15. J.B. Buse, R.R. Henry, J. Han, D.D. Kim, M.S. Fineman, and A.D. Baron Effects of exenatide (exendin-1) on glycaemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 27 2004 2628 2635
16. I. Carlstedt, and J.K. Sheehan Structure and macromolecular properties of cervical mucus glycoproteins Symp. Soc. Exp. Biol. 43 1989 289 316
17. S.Y. Chae, C.H. Jin, H.J. Shin, Y.S. Youn, S. Lee, and K.C. Lee Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery Bioconjug. Chem. 19 2008 334 341
18. K.B. Chalasani, G-J. Russell-Jones, A.K. Jain, P.V. Diwan, and S.K. Jain Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles J. Controlled Release 122 2007 141 150
19. K.B. Chalasani, G-J. Russell-Jones, S.K. Yandrapu, P.V. Diwan, and S.K. Jain A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin J. Controlled Release 117 2007 421 429
20. D.E. Chickering, and E. Mathiowitz Definitions mechanisms, and theories of bioadhesion E. Mathiowitz, D.E. Chickering, C.M. Lehr, Bioadhesive Drug Delivery Systems: Fundamentals, Novel Approaches, and Development 1999 Marcel Dekker New York 1 10
21. P.M. Claesson, E. Blomberg, J.C. Froberg, T. Nylander, and T. Arneberant Protein interactions at solid surfaces Adv. Colloid Interface Sci. 57 1995 161 227
22. 2+ in cultured epithelia Biochim. Biophys. Acta 1222 1994 147 158
23. R.A. Cone Barrier properties of mucus Adv. Drug Deliv. Rev. 61 2009 75 85
24. M. Copeman, J. Matuz, A.J. Leonard, J.P. Pearson, P.W. Dettmar, and A. Allen The gastroduodenal mucus barrier and its role in protection against luminal pepsins: the effect of 16,16 dimethyl prostaglandin E2, carbopolpolyacrylate, sucralfate and bismuth subsalicylate J. Gastroenterol. Hepatol. 9 1994 S55 S59
25. F. Cournarie, D. Auchere, D. Chevenne, B. Lacour, M. Seiller, and C. Vauthier Absorption and efficiency of insulin after oral administration of insulin-loaded nanocapsules in diabetic rats Int. J. Pharm. 242 2002 325 328
26. W. Creutzfeldt, and M. Nauck Gut hormones and diabetes mellitus Diabetes/Metabol. Rev. 8 1992 149 177
27. F. Cui, F. Qian, Z. Zhao, L. Yin, C. Tang, and C. Yin Preparation, characterization, and oral delivery of insulin loaded carboxylated chitosan grafted poly(methyl methacrylate) nanoparticles Biomacromolecules 10 2009 1253 1258
28. F. Cui, K. Shi, and L. Zhang Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation J. Controlled Release 114 2006 242 250
29. F. Cui, A-j. Tao, D-m. Cun, L-q. Zhang, and K. Shi Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery J. Pharm. Sci. 96 2006 421 427
30. C. Damge, P. Maincent, and N. Ubrich Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats J Controlled Release 117 2007 271 280
31. C. Damge, C. Michel, M. Aprahamian, and P. Couvreur New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier Diabetes 37 1988 246 251
32. C. Damge, C. Pinto, and P. Maincent Nanoparticle strategies for the oral delivery of insulin Expert Opin. Drug Deliv. 5 2008 45 68
33. M. Davidovich-Pinhas, O. Harari, and H. Bianco-Peled Evaluating the mucoadhesive properties of drug delivery systems based on hydrated thiolated alginate J. Controlled Release 136 2009 38 44
34. C.F. Deacon, M.A. Nauck, M. Toft-Nielsen, L. Pridal, B. Willms, and J.J. Holst Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects Diabetes 44 1995 1126 1131
35. N.V. Efremova, Y. Huang, N.A. Peppas, and D.E. Leckband Direct measurement of interactions between tethered poly(ethylene glycol) chains and adsorbed mucin layers Langmuir 18 2002 836 845
36. D. Elahi, M. McAloon-Dyke, N.K. Fukagawa, G.S. Meneilly, A.L. Sclater, K.L. Minaker, J.F. Habener, and D.K. Andersen The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects Regul. Pept. 51 1994 63 74
37. R.M. Elliott, L.M. Morgan, J.A. Tredger, S. Deacon, J. Wright, and V. Marks Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns J. Endocrinol. 138 1993 159 166
38. H. Elrick, L. Stimmler, C.J. Hlad, and Y. Arai Plasma insulin responses to oral and intravenous glucose administration J Clin Endocrinol Metab 24 1964 1076 1082
39. J. Eng, W.A. Kleinman, L. Singh, and J.P. Raufman Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom: further evidence for an exendin receptor on dispersed acini from guinea pig pancreas J. Biol. Chem. 267 1992 7402 7405
40. L.M. Ensign, R. Cone, and J. Hanes Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers Adv. Drug Deliv. Rev. 2012 10.1016/j.addr.2011.12.009
41. A. Fasano, C. Fiorentini, G. Donelli, S. Uzzau, J.B. Kaper, K. Margaretten, X. Ding, S. Guandalini, L. Comstock, and S.E. Goldblum Zonula occludens toxin modulates tight junctions through protein kinase c dependent actin reorganization In Vitro J. Clin. Invest. Inc. 96 1995 710 720
42. A. Fasano, and S. Uzzau Modulation of intestinal tight junctions by zona occludens toxin permits enteral administration of insulin and other macromolecules in an animal model J. Clin. Invest. 99 1997 1158 1164
43. C.H. Fazen, D. Valentin, T.J. Fairchild, and R.P. Doyle Oral delivery of the appetite suppressing peptide hPYY(3-36) through the vitamin B12 uptake pathway J. Med. Chem. 54 2011 8707 8711
44. E.J. Feskens, and D. Kromhout Hyperinsulinemia, risk factors, and coronary heart disease. The Zutphen Elderly Study Arterioscler. Thromb. 14 1994 1641 1647
45. A.C. Foss, T. Goto, M. Morishita, and N.A. Peppas Development of acrylic-based copolymers for oral insulin delivery Eur. J. Pharm. Biopharm. 57 2004 163 169
46. J.S. Freeman Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus Cleveland Clin. Med. 76 2009 S12 S19
47. G.H. George, and G.C. Oleg Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus Curr. Med. Chem. 10 2003 2471 2483
48. M.P. Gilbert, and R.E. Pratley Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus Eur. J. Intern. Med. 20 2009 S309 S318
49. J. Girard The incretins: From the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions Diabetes Metab. 34 2008 550 559
50. R.R. Henry, B. Gumbiner, T. Ditzler, P. Wallace, R. Lyon, and H.S. Glauber Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-month outpatient trial Diabetes Care 16 1993 21 31
51. K.D. Hinds, and S.W. Kim Effects of PEG conjugation on insulin properties Adv. Drug Deliv. Rev. 54 2004 505 530
52. S.-J. Hwang, H. Park, and K. Park Gastric retentive drug delivery systems Crit. Rev. Ther. Drug. Carrier Syst. 15 1998 243 286
53. H. Ichikawa, and N.A. Peppas Novel complexation hydrogels for oral peptide delivery: In vitro evaluation of their cytocompatibility and insulin transport enhancing effects using Caco-2 cell monolayers J. Biomed. Mater. Res. 67A 2003 609 617
54. K. Ikesue, P. Kopeckova, and J. Kopecek Degradation of proteins by guinea pig intestinal enzymes Int J. Pharm. 30 1993 171 179
55. M. Federwisch, M.L. Dieken, and P.D. Meyts Insulin and Related Proteins-Structure to Function and Pharmacology 2002 Kluwer Academic Publishers The Netherlands
56. Diabetes Atlas, International Diabetes Federation, fifth ed., 2011
57. S.E. Inzucchi, and D.K. McGuire New drugs for the treatment of diabetes mellitus. Part II. Incretin-based therapy and beyond Circulation 117 2008 574 584
58. H. Iyer, A. Khedkar, and M. Verma Oral insulin-a review of current status Diabetes Obes. Metab. 12 2010 179 185
59. C.-H. Jin, S. Son, T.H. Kim, K.A. Um, Y.S. Youn, S. Lee, and K.C. Lee A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice J. Controlled Release 133 2009 172 177
60. N. Jordan, J. Newton, J. Pearson, and A. Allen A novel method for the visualization of the in situ mucus layer in rat and man Clin. Sci. 95 1998 97 106
61. C.B. Juhl, O. Schmitz, S. Pincus, J.J. Holst, J. Veldhuis, and N. Porksen Short-term treatment with GLP-1 increases pulsatile insulin secretion in Type II diabetes with no effect on orderliness Diabetologia 43 2000 583 588
62. N.J. Kavimandan, E. Losi, and N.A. Peppas Novel delivery system based on complexation hydrogels as delivery vehicles for insulin-transferrin conjugates Biomaterials 27 2006 3846 3854
63. D.M. Kendall, M.C. Riddle, J. Rosenstock, D. Zhaung, D.D. Kim, M.S. Fineman, and A.D. Baron Effects of exenatide (exendin-4) on glycaemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 28 2005 1083 1091
64. S. Kerss, A. Allen, and A. Garner A simple method for measuring thickness of the mucus gel layer adherent to rat, frog and human gastric mucosa: influence of feeding, prostaglandin, N-acetylcysteine and other agents Clin. Sci. (Lond.) 63 1982 187 195
65. E-S. Khafagy, M. Morishita, Y. Onuki, and K. Takayama Current challenges in non-invasive insulin delivery systems: a comparative review Adv. Drug Deliv. Rev. 59 2007 1521 1546
66. V.V. Khutoryanskiy Advances in mucoadhesion and mucoadhesive polymers Macromol. Biosci. 11 2011 748 764
67. M. Kidron, S. Dinh, Y. Menachem, R. Abbas, B. Variano, M. Goldberg, E. Arbit, and H. Bar-On A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects Diabet. Med. 21 2004 354 357
68. T.J. Kieffer, C.H.S. Mcintosh, and R.A. Pederson Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide-1 in vitro and in vivo by dipeptidyl peptidase-IV Endocrinology 136 1995 3585 3596
69. B. Kim, and N.A. Peppas Poly(ethylene glycol)-containing hydrogels as insulin delivery carriers AAPS Pharm. Sci. 2000 S-S2394
70. B.Y. Kim, J.H. Jeong, and K. Park Bioadhesive interaction and hypoglycemic effect of insulin-loaded lectin-microparticle conjugates in oral insulin delivery system J. Controlled Release 102 2005 525 538
71. S.J. Kim, K. Winter, C. Nian, M. Tsuneoka, Y. Koda, and C.H. McIntosh Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of Bax expression J. Biol. Chem. 280 2005 22297 22307
72. W. Kim, and J.M. Egan The role of incretins in glucose homeostasis and diabetes treatment Pharmacol. Rev. 60 2008 470 512
73. L.L. Kjems, J.J. Holst, A. Volund, and S. Madsbad The influence of GLP-1 on glucose-stimulated insulin secretion effects on βcell sensitivity in type 2 and nondiabetic subjects Diabetes 52 2003 380 386
74. F.K. Knop, T. Vilsboll, and J.J. Holst Incretin-based therapy of type 2 diabetes mellitus Curr. Protein Pept. Sci. 10 2009 46 55
75. B. Kreymann, G. Williams, M.A. Ghatei, and S.R. Bloom Glucagon-like peptide-1 7-36: a physiological incretin in man Lancet 2 1987 1300 1304
76. B. Kriwet, and T. Kissel Poly(acrylic acid) microparticles widen the intercellular spaces of Caco-2 cell monolayers: an examination by confocal laser scanning microscopy Eur. J. Pharm. Biopharm. 42 1996 233 240
77. S. Krol, R. Ellis-Behnkeb, and P. Marchettic Nanomedicine for treatment of diabetes in an aging population: state-of-the-art and future developments Maturitas 2011 10.1016/j.maturitas.2011.12.004
78. S.K. Lai, D.E. O'Hanlon, S. Harrold, S.T. Man, Y.Y. Wang, R. Cone, and J. Hanes Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus Proc. Natl. Acad. Sci. U. S. A. 104 2007 1482 1487
79. S.K. Lai, Y-Y. Wang, and J. Hanes Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues Adv. Drug Deliv. Rev. 61 2009 158 171
80. P. Langgath, V. Bohner, J. Heizmann, H.P. Merkle, S. Wolffram, G.L. Amidon, and S. Yamashita The challenge of proteolytic enzymes in intestinal peptide delivery J. Controlled Release 46 1997 39 57
81. H. Liu, R. Tang, W.S. Pan, Y. Zhang, and H. Liu Potential utility of various protease inhibitors for improving the intestinal absorption of insulin in rats J. Pharm. Pharmacol. 55 2003 1523 1529
82. A.M. Lowman, M. Morishita, M. Kajita, T. Nagai, and N.A. Peppas Oral delivery of insulin using pH-responsive complexation gels J. Pharm. Sci. 88 1999 933 937
83. H.L. Lueßen, B.J. de Leeuw, D. Perard, C-M. Lehr, A.G. de Boer, J.C. Verhoef, and H.E. Junginger Mucoadhesive excipients in peroral peptide drug delivery. I. Influence of mucoadhesive excipients on the proteolytic activity of intestinal enzymes Eur. J. Pharm. Sci. 4 1996 117 128
84. Z. Ma, T.M. Lim, and L.Y. Lim Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats Int. J. Pharm. 293 2005 271 280
85. J.L. Madara Regulation of the movement of solutes across tight junctions Annu. Rev. Physiol. 60 1998 143 159
86. A. Makhlof, Y. Tozukaa, and H. Takeuchia Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery Eur. J. Pharm. Sci. 42 2011 445 451
87. M. Malmsten, E. Blomberg, P. Claesson, I. Carlstedt, and I. Ljusergren J. Colloid Interface Sci. 151 1992 579
88. M. Mesiha, F. Plakogiannis, and S. Vejosoth Enhanced oral absorption of insulin from desolvated fatty acid-sodium glycocholate emulsions Int. J. Pharm. 111 1994 213 216
89. L.M. Morgan The role of gastrointestinal hormones in carbohydrate and lipid metabolism and homeostasis: effects of gastric inhibitory polypeptide and glucagon-ike peptide-1 Biochem.Soc.Trans. 26 1998 216 222
90. M. Morishita, T. Goto, N.A. Peppas, J.I. Joseph, M.C. Torjman, C. Munsick, K. Nakamuara, T. Yamagata, K. Takayama, and A.M. Lowman Mucosal insulin delivery systems based on complexation polymer hydrogels: effect of particle size on insulin enteral absorption J. Controlled Release 97 2004 115 124
91. M. Morishita, I. Morishita, K. Takayama, Y. Machida, and T. Nagai Site-dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin Biol. Pharm. Bull. 16 1993 68 72
92. M. Morishita, T. Goto, K. nakamura, A.M. Lowman, K. Takayama, and N.A. Peppas Novel oral insulin delivery systems based on complexation polymer hydrogels: Single and multiple administration studies in type 1 and 2 diabetic rats J. Controlled Release 110 2006 587 594
93. M.A. Nauck, E. Bartels, C. Orskov, R. Ebert, and W. Creutzfeldt Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 (7-36) amide infused at near-physiolgical insulinotropic hormone and glucose concentrations J. Clin. Endocr. Metabol. 76 1993 912 917
94. M. Nauck, W.E. Schmidt, R. Ebert, J. Strietzel, P. Cantor, G. Hoffmann, and W. Creutzfeldt Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8 J. Clin. Endocrinol. Metab. 69 1989 654 662
95. M.A. Nauck, M.M. Heimsaat, K. Behle, J.J. Holst, M.S. Nauk, R. Ritzel, M. Hufner, and W.H. Schmiegel Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers J. Clin. Endocrinol. Metab. 87 2002 1239 1246
96. H-N. Nguyen, S.P. Wey, J.H. Juang, K. Sonaje, Y.C. Ho, E.Y. Chuang, C.W. Hsu, T.C. Yen, K.J. Lin, and H.W. Sung The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo Biomaterials 32 2011 2673 2682
97. P.L. Nicklin, W.J. Irwin, I.F. Hassan, and M. Mackay Development of a minimum-calcium Caco-2 monolayer model: calcium and magnesium ions retard the transport of pamidronate Int. J. Pharm. 123 1995 187 197
98. F.P. O'Harte, Y.H. Abdel-Wahab, J.M. Conlon, and P.R. Flatt Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells Biochim. Biophys. Acta 1425 1998 319 327
99. C. Oskov, A. Wettergren, and J.J. Holst Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day Scand. J. Gastroenterol. 31 1996 665 670
100. D.R. Owens, B. Zinman, and G.B. Bolli Insulins today and beyond Lancet 358 2001 739 746
101. Y. Pan, Y-j. Li, and Zhao H-y. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo Int. J. Pharm. 249 2002 139 147
102. W. Paul, and C.P. Sharma Tricalcium phosphate delayed release formulation for oral delivery of insulin: a proof-of-concept study J. Pharm. Sci. 97 2008 875 882
103. R.A. Pederson, T.J. Kieffer, R. Pauly, H. Kofod, J. Kwong, and C.H. McIntosh The enteroinsular axis in dipeptidyl peptidase IV-negative rats Metabolism 45 1996 1335 1341
104. E. Perez, and J.E. Proust Forces between mica surfaces covered with adsorbed mucin across aqueous solution J. Colloid Interface Sci. 118 1987 182 191
105. A. Peters Incretin-based therapies: review of current clinical trial data Am. J. Med. 123 2010 S28 S37
106. H. Pinto-Alphandary, M. Aboubakar, and D. Jaillard Visualization of insulin-loaded nanocapsules: in vitro and in vivo studies after oral administration to rats Pharm. Res. 20 2003 1071 1084
107. R.A. Pittner, C.X. Moore, S.P. Bhavsar, B.R. Gedulin, P.A. Smith, C.M. Jodka, D.G. Parkes, J.R. Paterniti, V.P. Srivastava, and A.A. Young Effects of PYY[3-36] in rodent models of diabetes and obesity Int. J. Obes. 28 2004 963 971
108. G. Ranaldi, I. Marigliano, I. Vespignani, G. Perozzi, and Y. Sambuy The effect of chitosan and other polycations on tight junction permeability in the human intestinal Caco-2 cell line J. Nutr. Biochem. 13 2002 157 167
109. C.P. Reis, F.J. Veiga, and A.J. Ribeiro Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response J. Pharm. Sci. 97 2008 5290 5305
110. M.R. Rekha, and C.P. Sharma Glutamine-chitosan microparticles as oral insulin delivery matrix: in vitro characterization J. Appl. Polym. Sci 122 2011 2374 2382
111. M.R. Rekha, and C.P. Sharma Challenges and advances in nanoparticle-based oral insulin delivery Expert Rev. Med. Dev. 6 2009 665 676
112. M.R. Rekha, and C.P. Sharma pH sensitive succinyl chitosan microparticles: a preliminary investigation towards oral insulin delivery Trends Biomater. Artif. Organs 21 2008 107 115
113. M.R. Rekha, and C.P. Sharma Phthalyl chitosan-poly(ethylene oxide) semi-interpenetrating polymer network microparticles for oral protein delivery: an in vitro characterization J. Appl. Polym. Sci. 110 2008 2787 2795
114. M.R. Rekha, and C.P. Sharma Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption J. Controlled Release 135 2009 144 151
115. S. Sajeesh, K. Bouchemal, V. Marsaud, C. Vauthier, and C.P. Sharma Cyclodextrin complexed insulin encapsulated hydrogel microparticles: an oral delivery system for insulin J. Controlled Release 147 2010 377 384
116. S. Sajeesh, and C.P. Sharma Novel pH responsive polymethacrylic acid-chitosan-polyethylene glycol nanoparticles for oral peptide delivery J. Biomed. Mater. Res. 76 2006 298 305
117. S. Sajeesh, C. Vauthier, C. Gueutin, G. Ponchel, and C.P. Sharma Thiol functionalized polymethacrylic acid-based hydrogel microparticles for oral insulin delivery Acta Biomater. 6 2010 3072 3080
118. B. Sarmento, S. Martins, D. Ferreira, and E.B. Souto Oral insulin delivery by means of solid lipid nanoparticles Int. J. Nanomed. 2 2007 743 749
119. B. Sarmento, A. Ribeiro, and F. Veiga Oral bioavailability of insulin contained in polysaccharide nanoparticles Biomacromolecules 8 2007 3054 3060
120. D. Shah, and W.-C. Shen Transcellular delivery of an insulin-transferrin conjugates in enterocyte-like Caco-2 cells J. Pharm. Sci. 85 1996 1306 1311
121. J.D. Smart The basics and underlying mechanisms of mucoadhesion Adv. Drug Deliv. Rev. 57 2005 1556 1568
122. K. Sonaje, K.J. Lin, M.T. Tseng, S.P. Wey, F.Y. Su, E.Y. Chuang, C.W. Hsu, and H.W. Sung Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins Biomaterials 32 2011 8712 8721
123. K. Sonaje, Y-H. Lin, and J-H. Juang In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery Biomaterials 30 2009 2329 2339
124. T.A. Sonia, M.R. Rekha, and C.P. Sharma Bioadhesive hydrophobic chitosan microparticles for oral delivery of insulin: in vitro characterization and in vivo uptake studies J. Appl. Polym. Sci. 119 2011 2902 2910
125. R.E. Steinert, B. Poller, M.C. Castelli, K. Friedman, A.R. Huber, J. Drewe, and C. Beglinger Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects Clin. Pharm. Ther. 86 2009 644 650
126. J.G. Still Development of oral insulin: progress and current status Diabetes Metab. Res. Rev. 18 2002 S29 S37
127. H.-W. Sung, K. Sonaje, L.-W. Liao, and E.-Y. Chuang pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: from mechanism to therapeutic applications Acc. Chem. Res. 2012 10.1021/ar200234q
128. E.S. Swenson, W.B. Milisen, and W. Curatolo Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility Pharm. Res. 11 1994 1132 1142
129. I. Takei, and T. Kasatani Future therapy of diabetes mellitus Biomed. Pharmacother. 58 2004 578 581
130. K. Tatemoto, and V. Mutt Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides Nature 285 1980 417 418
131. D.J. Thornton, and J.K. Sheehan From mucins to mucus: toward a more coherent understanding of this essential barrier Proc. Am. Thorac. Soc. 1 2004 54 61
132. V.P. Torchilin Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discov. 4 2005 145 160
133. P. Verdugo Goblet cells secretion and mucogenesis Annu. Rev. Physiol. 52 1990 157 176
134. E.J. Verspohl Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors Pharmacol. Ther. 124 2009 113 138
135. T. Vilsboll, H. Agerso, T. Krarup, and J.J. Holst Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects J. Clin. Endocrinol. Metab. 88 2003 220 224
136. K. Whitehead, N. Karr, and S. Mitragotri Safe and effective permeation enhancers for oral drug delivery Pharm. Res. 25 2008 1782 1788
137. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King Global prevalence of diabetes Diabetes Care 27 2004 1047 1053
138. F. Williams, and M. Saffran Insulin in the drinking water of rats Drug Deliv. 3 1996 81 85
139. C.Q. Xia, J. Wang, and W.-C. Shen Hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats J. Pharmacol. Exp. Ther. 295 2000 594 600
140. A. Yamamoto, T. Taniguchi, K. Rikyuu, T. Tsuji, T. Fujita, M. Murakami, and S. Muranishi Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats Pharm. Res. 11 1994 1496 1500
141. K. Yoncheva, E. Lizarraga, and J.M. Iache Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties Eur. J. Pharm. Sci. 24 2005 411 419
142. Y.S. Youn, S.Y. Chae, S. Lee, M.J. Kwon, H.J. Shin, and K.C. Lee Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation Eur. J. Pharm. Biopharm. 68 2008 667 675
143. N. Zhang, Q. Ping, G. Huang, W. Xua, Y. Chenga, and X. Hana Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin Int. J. Pharm. 327 2006 153 159